Sana Biotechnology, Inc. saw its stock price plummet by 5.09% during intraday trading on Wednesday. The significant drop came amid negative sentiment from Wall Street analysts.
The sell-off followed news that investment firm H.C. Wainwright reduced its price target for Sana Biotechnology from $9 to $7, representing a substantial downward revision of approximately 22%. Analyst price target cuts often signal reduced confidence in a company's future growth prospects and valuation, prompting investors to reconsider their positions.